CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
The CDK12-BRD4S-TGFβ signaling axis represents a key regulatory module that promotes metastatic progression and can be targeted by BET or TGFβ pathway inhibitors for treating CDK12-deficient cancers.
Authors
- Huaiyuan Liang (ORCID: https://orcid.org/0009-0006-9578-8970)
- Haojie Huang (ORCID: https://orcid.org/0000-0003-2751-6413)
- Ting Wei (ORCID: https://orcid.org/0000-0001-9008-0339)
- Hao Li (ORCID: https://orcid.org/0000-0003-0541-562X)
- Dan Xia (ORCID: https://orcid.org/0009-0007-7568-9649)
- Liguo Wang (ORCID: https://orcid.org/0000-0003-2072-4826)
- Hongshan Guo (ORCID: https://orcid.org/0000-0003-2799-2989)
- Jindan Luo (ORCID: https://orcid.org/0000-0002-2593-5676)
- Rui Sun (ORCID: https://orcid.org/0000-0002-7185-1422)
- Jiandong Liu (ORCID: https://orcid.org/0009-0006-1599-1216)
- Bai Yanfeng (ORCID: https://orcid.org/0009-0002-4845-3415)
Institutions
- Qingdao University (CN)
- Mayo Clinic (US)
- Central South University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Mayo Clinic in Arizona (US)
- Second Xiangya Hospital of Central South University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1158/0008-5472.can-25-1761
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00